Veeva Systems
VEEV
$163.31
-0.33%
Veeva Systems Inc. is a global leader in providing cloud-based software solutions exclusively for the life sciences industry, with core products including Veeva CRM for customer relationship management and Veeva Vault for content management. The company has established itself as a dominant, best-of-breed platform player by deeply understanding the complex regulatory and operational needs of pharmaceutical and biotechnology companies, effectively displacing legacy enterprise systems. The current investor narrative is sharply focused on a significant stock price correction, which has created a debate between viewing the decline as a structural threat to its niche dominance or a compelling long-term buying opportunity given its clear growth runway and entrenched customer relationships.…
VEEV
Veeva Systems
$163.31
Related headlines
VEEV 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veeva Systems's 12-month outlook, with a consensus price target around $212.30 and implied upside of +30.0% versus the current price.
Average Target
$212.30
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$131 - $212
Analyst target range
Analyst coverage is robust with 9 firms actively covering the stock, and the institutional ratings show a consensus that leans bullish, with recent actions including multiple 'Buy', 'Overweight', and 'Outperform' ratings from firms like Citigroup, TD Cowen, Truist Securities, Piper Sandler, Wells Fargo, and RBC Capital. The average revenue estimate for the coming period is $5.88 billion, with a tight range between $5.81 billion and $5.97 billion, indicating strong analyst conviction in the company's near-term financial trajectory. The wide dispersion between the trailing and forward PE multiples (36.72x vs. 16.07x) itself signals that analyst models and market expectations are baking in a significant earnings acceleration, which, if not realized, could lead to further volatility; however, the high target price assumptions likely embed confidence in Veeva's long-term doubling revenue goal and its ability to maintain industry leadership.
Bulls vs Bears: VEEV Investment Factors
The investment debate for Veeva Systems centers on whether its severe price correction represents a structural breakdown or a compelling entry point for a high-quality compounder. The bearish evidence is currently more forceful, dominated by a powerful technical downtrend and concrete signs of growth deceleration and margin pressure. However, the bullish case is underpinned by exceptionally strong fundamentals: a fortress balance sheet, superior profitability, and a dominant niche position. The single most important tension is the market's expectation of an earnings reacceleration (priced into the 16x forward P/E) versus the risk that growth continues to moderate, invalidating that optimistic scenario. The resolution of this growth trajectory will determine the stock's direction.
Bullish
- Fortress Balance Sheet & Cash Flow: Veeva has a pristine balance sheet with a debt-to-equity ratio of 0.013 and a current ratio of 4.89, providing immense financial flexibility. The company generates robust free cash flow of $1.39 billion TTM, enabling it to invest through cycles and weather downturns without liquidity concerns.
- High-Quality, Profitable Growth: The company maintains superior profitability with a net margin of 29.21% and a gross margin of 74.46%. Despite a stock price decline of 45.85% over six months, Q4 revenue grew 15.96% YoY to $835.95 million, demonstrating resilient demand for its mission-critical software.
- Compelling Forward Valuation: The forward P/E of 16.07x is less than half the trailing P/E of 36.72x, indicating the market expects significant earnings growth. This forward multiple is now more reasonable for a company with Veeva's growth and profitability profile, especially compared to its historical premium valuations above 50x.
- Dominant Niche Market Position: Veeva is the global leader in cloud software for the life sciences industry, a highly regulated and sticky market. Its best-of-breed solutions, like Veeva CRM and Vault, have successfully displaced legacy systems, creating deep customer entrenchment and a long-term growth runway to double revenue by 2030.
Bearish
- Severe Technical Downtrend: The stock is in a severe bear market, down 45.85% over six months and trading just 7.3% above its 52-week low of $148.05. It has shown persistent negative relative strength (-10.64 points vs. SPY over one month), indicating sustained institutional selling and a lack of buying interest.
- Growth Deceleration & Margin Pressure: Revenue growth has decelerated sequentially, from 19.8% YoY in Q3 to 15.96% YoY in Q4. Concurrently, the operating margin compressed from 32.15% to 29.41%, raising questions about the sustainability of its high-margin growth model in a potentially more competitive environment.
- Premium Valuation Despite Correction: Even after the steep decline, Veeva's trailing P/E of 36.72x and P/S of 10.44x represent a significant premium to the broader market and many software peers. This leaves the stock vulnerable to further multiple compression if growth continues to slow or if investor sentiment remains risk-averse.
- High Dependence on Single Industry: Veeva's entire business is concentrated in the life sciences industry. While this provides deep expertise, it also creates concentration risk; any regulatory changes, funding pressures, or a downturn in biopharma R&D spending could disproportionately impact its revenue stream with no other markets to offset it.
VEEV Technical Analysis
The stock is in a pronounced and sustained downtrend, having declined 34.25% over the past year and a staggering 45.85% over the last six months. With a current price of $158.86, it is trading just 7.3% above its 52-week low of $148.05, positioning it in the lower extreme of its annual range, which suggests either a deep value opportunity or a stock experiencing fundamental deterioration that has yet to find a bottom. Recent momentum shows continued weakness, with the stock down 5.04% over the past month and 8.76% over the past three months, indicating the selling pressure has persisted even as the broader market (SPY up 5.6% over one month) has rallied, resulting in severe negative relative strength of -10.64 points. Key technical levels are clear: immediate support is the 52-week low of $148.05, while formidable resistance sits far above at the 52-week high of $310.5; a breakdown below $148 could trigger another leg down, while any sustained move above it would be a first sign of stabilization. The stock's beta of 0.924 indicates it has been slightly less volatile than the market during this downtrend, but its maximum drawdown of -50.55% highlights the extreme absolute price damage that has occurred, demanding careful risk management for any prospective position.
Beta
0.92
0.92x market volatility
Max Drawdown
-50.5%
Largest decline past year
52-Week Range
$148-$311
Price range past year
Annual Return
-31.9%
Cumulative gain past year
| Period | VEEV Return | S&P 500 |
|---|---|---|
| 1m | -2.8% | +3.3% |
| 3m | -9.9% | +6.9% |
| 6m | -39.6% | +12.4% |
| 1y | -31.9% | +23.4% |
| ytd | -25.6% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VEEV Fundamental Analysis
Revenue growth remains healthy but has shown signs of sequential deceleration; the most recent quarterly revenue (Q4 FY2026) was $835.95 million, representing a solid 15.96% year-over-year increase, yet this marks a slowdown from the 19.8% YoY growth seen in the prior quarter (Q3 FY2026 revenue of $811.24 million). Segment data reveals the Subscription Services for Veeva Commercial Cloud, at $644.63 million, is the primary growth engine, vastly outweighing the $95.04 million from Professional Services, indicating the business model is heavily weighted toward high-margin, recurring software revenue. The company is highly profitable with robust margins, reporting net income of $244.20 million and a gross margin of 74.46% for the latest quarter; however, the operating margin of 29.41% has compressed from 32.15% in the prior quarter, suggesting potential investments or cost pressures. The net margin stands at a strong 29.21%, and the trailing twelve-month free cash flow is a substantial $1.39 billion, demonstrating excellent cash generation. Balance sheet health is exceptional, with a minimal debt-to-equity ratio of 0.013 and a very strong current ratio of 4.89, indicating ample liquidity and a fortress-like financial position that provides significant flexibility to navigate market challenges or invest for growth.
Quarterly Revenue
$835951000.0B
2026-01
Revenue YoY Growth
+0.15%
YoY Comparison
Gross Margin
+0.74%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VEEV Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 36.72x, while the forward PE is significantly lower at 16.07x, indicating the market expects a substantial rebound in earnings growth over the next year, likely pricing in the recent stock decline and future profit expansion. Compared to sector averages, Veeva's trailing PE of 36.72x represents a significant premium, though this must be contextualized by its superior growth profile, high profitability (net margin of 28.44%), and dominant niche position within the healthcare software space. Historically, the stock's own valuation has contracted sharply from recent highs; for instance, its PE ratio was above 50x as recently as Q3 FY2026, meaning the current multiple near 37x is at a more moderate level within its own historical band, suggesting some of the previous optimism has been priced out, though it remains elevated compared to pure value plays.
PE
36.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 34x~117x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are currently moderate but rising. The primary concern is the sequential deceleration in revenue growth (from 19.8% to 15.96% YoY) coupled with operating margin compression (from 32.15% to 29.41%). While the company is still highly profitable, this trend, if it persists, could challenge its premium valuation. Furthermore, Veeva's business is entirely concentrated in the life sciences sector, creating revenue concentration risk; a slowdown in biopharma IT spending would have an immediate and direct impact. However, these risks are heavily mitigated by an exceptional balance sheet with minimal debt (D/E of 0.013) and massive liquidity (current ratio of 4.89).
Market & Competitive Risks are elevated. The stock's valuation, despite the correction, remains at a premium with a trailing P/E of 36.72x, leaving it vulnerable to further compression in a risk-off environment or if growth stocks continue to fall out of favor. Its beta of 0.924 suggests it is not immune to broader market moves. Competitively, while Veeva has a dominant niche position, the threat from larger enterprise software vendors or new entrants targeting the lucrative life sciences cloud market is a constant overhang. Recent news highlighting geopolitical uncertainty favoring defensive sectors over growth stocks like Veeva underscores this macro sensitivity.
The Worst-Case Scenario involves a continuation of the current downtrend fueled by a failure to reaccelerate growth. This could trigger a cascade of analyst downgrades and multiple compression. The specific chain would be: Q1 FY2027 earnings show growth decelerating further below 15% and margins contracting, leading to forward EPS estimate cuts. This breaks the narrative supporting the 16x forward P/E, causing the multiple to de-rate towards 12-14x. Combined with lower earnings, the stock could realistically revisit and break below its 52-week low of $148.05, testing levels last seen during the 2022 bear market. From the current price of $158.86, this implies a potential downside of -7% to -10% to the recent low, with a more severe bear case drawdown potentially reaching -25% to -30% if sentiment turns deeply negative.